1. Trial profile
GISSI-HF investigators. Lancet 2008; Aug 29 [Epub ahead of print]

2. Baseline characteristics of patients
GISSI-HF investigators. Lancet 2008; Aug 29 [Epub ahead of print]

3. Kaplan-Meier curves for time to all-cause death (A) and for time to all-cause death or admission to hospital for cardiovascular reasons (B)
PUFA=polyunsaturated fatty acids. *Estimates were calculated with a Cox proportional hazards model, with adjustment for admission to hospital for heart failure in the previous year, previous pacemaker, and aortic stenosis.
GISSI-HF investigators. Lancet 2008; Aug 29 [Epub ahead of print]

4. Secondary outcomes
GISSI-HF investigators. Lancet 2008; Aug 29 [Epub ahead of print]

5. Causes of death
GISSI-HF investigators. Lancet 2008; Aug 29 [Epub ahead of print]

6. for cardiovascular reasons
Predefined subgroup analysis-composite endpoint of all-cause death or admission to hospital
for cardiovascular reasons
GISSI-HF investigators. Lancet 2008; Aug 29 [Epub ahead of print]

7. Permanent treatment discontinuations and adverse drug reactions
GISSI-HF investigators. Lancet 2008; Aug 29 [Epub ahead of print]